| Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha TS Larsen, KF Iversen, E Hansen, AB Mathiasen, C Marcher, ... Leukemia research 37 (9), 1041-1045, 2013 | 97 | 2013 |
| Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report KF Iversen, PC Holdgaard, B Preiss, CG Nyvold, T Plesner haematologica 104 (9), e432, 2019 | 20 | 2019 |
| The real-world outcomes of multiple myeloma patients treated with daratumumab AG Szabo, TW Klausen, MB Levring, B Preiss, C Helleberg, MF Breinholt, ... PloS one 16 (10), e0258487, 2021 | 14 | 2021 |
| Clinically‐suspected cast nephropathy: A retrospective, national, real‐world study AG Szabo, J Thorsen, KF Iversen, CT Hansen, EM Teodorescu, ... American Journal of Hematology 95 (11), 1352-1360, 2020 | 13 | 2020 |
| The clinical course of multiple myeloma in the era of novel agents: a retrospective, single-center, real-world study AG Szabo, KF Iversen, S Möller, T Plesner Clinical Hematology International 1 (4), 220-228, 2019 | 12 | 2019 |
| Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59 K Brennan, KF Iversen, A Blanco-Fernández, T Lund, T Plesner, ... Cells 11 (21), 3365, 2022 | 5 | 2022 |
| The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy AG Szabo, J Thorsen, KF Iversen, MB Levring, B Preiss, C Helleberg, ... Blood 138, 3779, 2021 | 5 | 2021 |
| Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) A Spencer, KF Iversen, B Dhakal, M Creignou, J Chen, IH Hiemstra, ... Blood 140 (Supplement 1), 7320-7321, 2022 | 3 | 2022 |
| Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients KL Højholt, H Gregersen, AG Szabo, TW Klausen, MB Levring, B Preiss, ... Hematological Oncology 39 (4), 521-528, 2021 | 2 | 2021 |
| High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens KF Iversen, L Nederby, T Lund, T Plesner Clinical Hematology International 4 (3), 107-116, 2022 | 1 | 2022 |
| Nationwide implementation of lenalidomide maintenance in multiple myeloma: A retrospective, real‐world study M Harsløf, I Chanchiri, T Silkjær, UC Frølund, EM Teodorescu, KB Nielsen, ... eJHaem, 2024 | | 2024 |
| DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA KF Iversen, T Plesner Srpski medicinski časopis Lekarske komore 4 (4), 2023 | | 2023 |
| Lenalidomide Maintenance in Multiple Myeloma: A Retrospective, Nationwide, Real-World Study M Harsløf, I Chanchiri, T Silkjær, UC Frølund, EM Teodorescu, KB Nielsen, ... Blood 142, 1979, 2023 | | 2023 |
| The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies AG Szabo, J Thorsen, KF Iversen, MB Levring, C Helleberg, E Hermansen, ... EJHaem 4 (4), 1006-1012, 2023 | | 2023 |
| P-318 The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies AG Szabo, J Thorsen, KF Iversen, MB Levring, C Helleberg, E Hermansen, ... Clinical Lymphoma, Myeloma and Leukemia 23, S213, 2023 | | 2023 |
| GEN3014 (HexaBody®-CD38) versus daratumumab in patients with relapsed/refractory multiple myeloma: design of randomized head-to-head expansion cohort of phase 1/2 trial S Grosicki, B Dhakal, E Malek, M Creignou, W Jurczak, A Broijl, ... Clinical Lymphoma, Myeloma & Leukemia 2 (Suppl. 2), S62-S63, 2023 | | 2023 |
| P816: PHARMACODYNAMIC ACTIVITY OF GEN3014 (HEXABODY-CD38) IN PATIENTS WITH MULTIPLE MYELOMA SUPPORTS ENHANCED COMPLEMENT DEPENDENT CYTOTOXICITY OF GEN3014 COMPARED TO DARATUMUMAB IH Hiemstra, K Santegoets, M Janmaat, W Ten Hagen, R Sanchez, ... HemaSphere 7 (S3), e008261b, 2023 | | 2023 |
| PB2105: LENALIDOMIDE MAINTENANCE IN MULTIPLE MYELOMA: A RETROSPECTIVE, NATIONWIDE, REAL-WORLD STUDY M Harsløf, I Chanchiri, T Silkjær, UC Frølund, E Todorescu, K Grønbæk, ... HemaSphere 7 (S3), e4464961, 2023 | | 2023 |
| Casereport: Acute Hemolytic Transfusion Reaction as an atypical presentation of paroxysmal Cold Hemoglobinuria MT Bruun, U Sprogøe, KF Iversen | | 2023 |
| Resistance to daratumumab in patients with multiple myeloma KF Iversen | | 2023 |
